Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, PAVmed Inc. reported revenue of $0M, down 97.6% year over year. Operating margin was -30712.7% and net margin 564.8%, on a free-cash-flow margin of -7376.1% with capital expenditure at 43.7% of revenue. Every figure is computed directly from PAVM's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $0M | -30712.7% | 564.8% |
| FY2024 | $3M | -1482.9% | 1326.4% |
| FY2023 | $3M | -2751.8% | -2567.0% |
| FY2022 | $0M | -24161.0% | -23602.9% |
| FY2021 | $1M | -10878.6% | -10069.4% |
How does PAVM compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: A · ACHR · AEHR · AERG · AEVA · AIRI
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.